Search Result "Myelodysplastic syndrome (MDS)"
Implications of Somatic Mutations in the AML1/RUNX1 Gene in Myelodysplastic Syndrome (MDS): Future Molecular Therapeutic Directions for MDS
Journal: Current Cancer Drug Targets
Volume: 6 Issue: 6 Year: 2006 Page: 553-563
Author(s): Hironori Harada, Yuka Harada, Akiro Kimura
Immunosuppressive Therapy for Myelodysplastic Syndromes
Journal: Current Pharmaceutical Design
Volume: 18 Issue: 22 Year: 2012 Page: 3184-3189
Author(s): Christiane Dobbelstein,Arnold Ganser
Genome-wide Analysis of Myelodysplastic Syndromes
Journal: Current Pharmaceutical Design
Volume: 18 Issue: 22 Year: 2012 Page: 3163-3169
Author(s): Masashi Sanada,Seishi Ogawa
Lenalidomide for Treatment of Myelodysplastic Syndromes
Journal: Current Pharmaceutical Design
Volume: 18 Issue: 22 Year: 2012 Page: 3198-3203
Author(s): Rami S. Komrokji,Alan F. List
Biological Basis of Novel Therapies for Myelodysplastic Syndrome
Journal: Current Cancer Therapy Reviews
Volume: 2 Issue: 3 Year: 2006 Page: 199-209
Author(s): Eyal C. Attar, Karen K. Ballen
Drug Resistance and Methylation in Myelodysplastic Syndrome
Journal: Current Pharmaceutical Biotechnology
Volume: 8 Issue: 2 Year: 2007 Page: 77-81
Author(s): D. O. Vidal, L. F. Lopes, E. T. Valera
MicroRNA Dysregulation in the Myelodysplastic Syndromes
Journal: MicroRNA
Volume: 2 Issue: 3 Year: 2013 Page: 174-186
Author(s): Stephen S. Chung,Christopher Y. Park
Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Journal: Current Cancer Drug Targets
Volume: 7 Issue: 6 Year: 2007 Page: 541-558
Author(s): E. D. Warlick, B. D. Smith
Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes
Journal: Current Pharmaceutical Design
Volume: 23 Issue: 1 Year: 2017 Page: 135-169
Author(s): Karmen Stankov,Suncica Stankov,Jasmina Katanic
World Health Organization Classification of Myelodysplastic Syndromes
Journal: Current Pharmaceutical Design
Volume: 18 Issue: 22 Year: 2012 Page: 3149-3162
Author(s): Magdalena Czader,Attilio Orazi